Amgen filed a cross appeal in this long-running case on October 15, 2018. The appeal challenges, among other things, the district court’s previous judgement that Hospira had not infringed on another patent named in the original suit, US Patent Number 5,756,349, which covers the production of erythropoietin.
In 2017, a federal jury found that Hospira had infringed on Amgen’s US Patent Number 5,856,298, which covers erythropoietin, in producing batches of a biosimilar epoetin alfa, now approved as Retacrit.
At the time, the court had ordered Hospira to pay Amgen, the reference product sponsor, $70 million in damages.
Since then, the Delaware district court entered final judgement, in September 2018, against Hospira. The judgement included an additional $10 million in pre-judgement interest, plus post-judgement interest from September 2017 until Hospira satisfies the final judgement, computed daily and compounded annually at a rate of 1.31%.
The damages were decided based on the jury verdict in 2017 that Hospira had infringed upon an Amgen process patent by manufacturing 14 batches of erythropoietin outside of the protection of the Safe Harbor Act. Hospira had unsuccessfully argued during the trial that its batches of the drug were part of its FDA approval process, and thus protected under safe harbor.
After receiving the final judgement rule, Hospira had 30 days to respond, during which the biosimilar manufacturer filed an appeal to the Federal Circuit in Delaware.
Subsequently, Amgen filed a cross appeal on October 15, 2018. The appeal challenges, among other things, the district court’s previous judgement that Hospira had not infringed on another patent named in the original suit, US Patent Number 5,756,349, which covers the production of erythropoietin. The appeals have since been consolidated into a single case.
Due to the filing of a cross-appeal, there will be 4 rounds of appellate briefing, and Hospira’s opening brief is due on December 10, 2018.
To date, in Europe there are currently 3 biosimilar versions of epoetin alfa available on the market, sold as Silapo, Retacrit, and Epoetin Alfa Hexal/Abseamed/Binocrit. Conversely, the United States has only 1 approved biosimilar epoetin alfa, Retacrit, though no launch date has been made available in light of ongoing litigation.
Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo
March 6th 2024Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patient With MS Sues J&J Over ERISA Violation
February 14th 2024After a patient with multiple sclerosis (MS) was forced to pay exorbitant out-of-pocket costs for a brand name medication when she could’ve gotten a generic for way less, the patient filed a class action complaint against her employer, Johnson & Johnson (J&J), for violating the Employee Retirement Income Security Act of 1974 (ERISA).
Eye on Pharma: Fresh Biosimilar Lawsuits; FDA to Review Ustekinumab, Denosumab Biosimilars
January 11th 2024As Regeneron gears up for a legal battle with biosimilar competitors for its reference aflibercept, CareFirst files a lawsuit against Johnson & Johnson for restricting biosimilar ustekinumab competition; Celltrion and Accord BioPharma file with the FDA to approve their respective biosimilar candidates.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).